Tenax Therapeutics(TENX)
CHAPEL HILL, NCBiotechnology
Focus: Tenax Therapeutics is a newly public (2024) cardiovascular-focused biotech developing small-molecule therapeutics for pulmonary hypertension, heart failure, and traumatic brain injury. The company is in early-to-mid stage clinical development with no marketed products.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Tenax Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Tenax Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$0K
Pipeline & Clinical Trials
Levosimendan
Heart DecompensationClinical Trials (1)
NCT02973620Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
N/AHelp build intelligence for Tenax Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.